On 10 – 11 September, MyMeds&Me is looking forward to participating in the World Drug Safety Congress Europe, hosted in Amsterdam. Attended by key players across the pharma industry, the WDSC brings together more than 550 drug safety, pharmacovigilance and analytics companies within the biopharma sector.
This year, WDSC focuses on addressing key challenges for drug safety. Discussions will include ways in which technology can enable pharmacovigilance and explore how innovation can improve patient safety.
Representing MyMeds&Me this year is Chief Scientific Officer and Co-Founder Trevor Gibbs, who will be speaking on Transforming product risk management globally by digitising the capture of adverse events; Tuesday 10th September.
Relevant data is at the heart of drug safety, but often data quality, intake and processing leave much to be desired. Pertinent data capture is required as part of RMP or REMS commitments. In addition, Regulatory Authorities will expect evidence that this has been done. Trevor’s talk will look at the opportunity to transform the collection, processing and ultimately product risk management.
In addition, on Wednesday 11 September, Accenture & MyMeds&Me will be co-hosting a roundtable. The session will explore how strategies for digital capture of data can streamline PV operations and produce valuable, compliant and scalable results for the sponsor. The roundtable will be led by April Davis, Principal Director, Global Life Sciences for Accenture and Trevor Gibbs, CSO at MyMeds&Me.
Book your place and download the agenda here: https://www.terrapinn.com/conference/world-drug-safety-congress-europe/index.stm
